

The incretin receptors for GLP-1 and GIP are essential for the sustained metabolic actions of vildagliptin in mice

Grace Flock, Laurie L. Baggio, Christine Longuet and Daniel J. Drucker

The Samuel Lunenfeld Research Institute, Department of Medicine, Mount Sinai Hospital and the Banting and Best Diabetes Center, University of Toronto, Toronto, Canada.

Running title: Incretin receptors and mechanisms of DPP-4 action

Address correspondence to:

Dr. Daniel J. Drucker
Mount Sinai Hospital
SLRI Room 975C
600 University Avenue
Toronto Ontario
M5G 1X5

Received for publication 22 May 2007 and accepted in revised form 20 August 2007.

Additional information can be found in an online appendix at <http://diabetes.diabetesjournals.org>.

Abstract

Objective: DPP4 inhibitors (DPP-4i) lower blood glucose in diabetic subjects however the mechanism of action through which these agents improve glucose homeostasis remains incompletely understood. Although GLP-1 and GIP represent important targets for DPP4 activity, whether additional substrates are important for the glucose-lowering actions of DPP4 inhibitors remains uncertain.

Research Design and Methods: We examined the efficacy of continuous vildagliptin administration in wildtype (WT) and dual incretin receptor knockout (DIRKO) mice after 8 weeks of a high fat (HF)-diet.

Results: Vildagliptin had no significant effect on food intake, energy expenditure, body composition, body weight gain or insulin sensitivity in WT or DIRKO mice. However glycemic excursion after oral glucose challenge was significantly reduced in WT but not in DIRKO mice after vildagliptin treatment. Moreover, vildagliptin increased levels of glucose-stimulated plasma insulin, and reduced levels of cholesterol and triglycerides in WT but not in DIRKO mice. Vildagliptin treatment reduced the hepatic expression of genes important for cholesterol synthesis and fatty acid oxidation, including Phosphomevalonate kinase (Mvk), Acyl-Coenzyme Dehydrogenase medium chain (Acadm), Mevalonate (diphospho)decarboxylase (Mvd), and Acyl-CoA Synthetase (Acs11) in WT but not in DIRKO mice. However, vildagliptin also reduced levels of hepatic mRNA transcripts for Farnesyl di-phosphate transferase (Fdft1), Acetyl Co-enzyme A Acyltransferase 1 (Acaa1) and Carnitine palmitoyl transferase 1 (Cpt 1) in DIRKO mice. No direct effect of GLP-1R agonists was detected on cholesterol or triglyceride synthesis and secretion in WT hepatocytes.

Conclusions: These findings illustrate that although GLP-1 and GIP receptors represent the dominant molecular mechanisms for transducing the glucoregulatory actions of DPP4 inhibitors, prolonged DPP4 inhibition modulates the expression of genes important for lipid metabolism independent of incretin receptor action *in vivo*.

Introduction

Incretins are peptide hormones secreted following meal ingestion that potentiate glucose-stimulated insulin secretion. The two predominant incretins are glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). GIP and GLP-1 act via specific receptors on β -cells to increase insulin biosynthesis and secretion, thereby maintaining the ability of the endocrine pancreas to regulate the disposal and storage of energy following nutrient absorption (1). Both GIP and GLP-1 also exert actions on other cell types that impact energy homeostasis. GIP enhances energy storage in adipocytes whereas GLP-1 regulates glucose homeostasis via inhibition of glucagon secretion and gastric emptying, and induction of satiety leading to long term control of body weight (1).

The multiple actions of GLP-1 that promote reduction of blood glucose have fostered attempts to use the native peptide for the treatment of type 2 diabetes mellitus (T2DM). Intermittent or continuous administration of GLP-1 reduced blood glucose and HbA1c and improved β -cell function, demonstrating the feasibility of using GLP-1 therapy for the treatment of T2DM (2; 3). Nevertheless, as bioactive GLP-1 is rapidly eliminated from the circulation due to a combination of enzymatic degradation and renal clearance (4; 5), there is considerable interest in strategies that enhance GLP-1 action without the need for continuous administration of the native peptide.

One such approach involves the administration of degradation-resistant GLP-1 receptor (GLP-1R) agonists, such as exendin-4 (6). Synthetic exendin-4 (Exenatide) has been evaluated in clinical trials for the treatment of patients with T2DM not adequately controlled on one or more anti-diabetic agents. Twice daily administration of Exenatide via subcutaneous injection for 6 months significantly lowered blood glucose and HbA1c, in association with weight loss in the majority of treated subjects (7). Hence, there is increasing interest in developing long-acting GLP-1R agonists for the treatment of T2DM.

An alternative approach for enhancing incretin action involves the development of inhibitors of dipeptidyl peptidase-4 (DPP4), the principal enzyme responsible for inactivation of both GIP and GLP-1. Both incretin peptides contain an alanine residue at position 2, and are rapidly inactivated by N-terminal cleavage following secretion from gut endocrine cells (8-10). The importance of endogenous DPP4 for glucose homeostasis is illustrated by the phenotype of mice with targeted inactivation of the DPP4 gene. DPP4 knockout mice exhibit reduced glycemic excursion following glucose loading, enhanced levels of GLP-1 and glucose-stimulated insulin secretion, and resistance to diet-induced obesity (11; 12). Furthermore, DPP4 inhibitors lower levels of blood glucose and improve β -cell function in human subjects with T2DM (13), reviewed in (7; 14). Accordingly, there is considerable interest in understanding the mechanism of action and therapeutic potential of DPP4 inhibitors in the treatment of diabetes.

Although GLP-1 and GIP are important targets for the acute glucoregulatory actions of DPP4 inhibitors, numerous additional peptides may also be DPP4 substrates, and represent putative mediators of the anti-diabetic actions of DPP4 (15). For example, inhibition of DPP4 activity augmented insulin secretion following exogenous administration of GLP-1, GIP, gastrin-releasing peptide (GRP) and pituitary adenylate cyclase activating polypeptide (PACAP) in mice (16). Furthermore, the proglucagon-derived peptide oxyntomodulin is also a substrate for DPP4 (17), and is capable of stimulating insulin secretion *in vivo* (18). Hence, the extent to which additional substrates, beyond GLP-1 and GIP, contribute to the glucoregulatory actions of DPP4 inhibitors, remains uncertain (19).

To ascertain the importance of specific DPP4 substrates for the action of DPP4 inhibitors *in vivo*, we have used a genetic approach in mice. The actions of four chemically distinct DPP4 inhibitors on glycemic excursion and insulin secretion were examined in WT mice, and in mice with genetic disruption of incretin receptor

genes. Acute inhibition of DPP4 activity was associated with reduction of glycemic excursion following oral glucose loading in WT mice, and in both *Glp1r*^{-/-} and *Gipr*^{-/-} mice (20). In contrast, double incretin receptor knockout (DIRKO) mice failed to exhibit enhancement of insulin secretion or reduction of blood glucose following inhibition of DPP4 activity, implying that the GLP-1 and GIP receptors together are essential for the acute gluoregulatory actions of DPP4 inhibitors (20). Nevertheless, it remains possible that more sustained inhibition of DPP-4 activity is associated with the recruitment and emergence of additional pathways, in addition to the GLP-1 and GIP receptors, that contribute to gluoregulatory actions *in vivo*. Accordingly, we have now examined the metabolic consequences of chronic administration of the DPP4 inhibitor vildagliptin for 8 weeks in high fat fed WT and DIRKO mice.

Research Design and Methods

Animal Studies. The generation and characterization of DIRKO mice has been described previously (20; 21). Male WT (C57BL/6 from Charles River, Montreal, Quebec), and DIRKO mice were housed, 1 mouse per cage under a light/dark cycle of 12 h in the Toronto General Hospital animal facility with free access to food and water, except where noted. All WT mice used for these studies were acclimatized to the animal facility for several weeks prior to analysis. Four week old mice were fed *ad libitum* a high fat (HF) diet, with 45% kCal from fat, (Research Diets, New Brunswick, NJ) for 6 weeks, following which groups of mice were randomized to receive either regular water, or water continuously supplemented with vildagliptin, 1 μ mol/ml for eight weeks. Assessment of fat and lean mass was carried out using a whole body magnetic resonance analyzer (Echo Medical Systems, Houston, TX). All procedures were conducted according to protocols and guidelines approved by the Toronto General Hospital and Mount Sinai Hospital Animal Care Committees.

Glucose Tolerance Tests and Measurement of Plasma Insulin, Glucagon and Lipid Levels. Following an overnight fast, glucose (1.5 mg/g

body weight) was administered orally through a gavage tube. A blood sample was drawn from a tail vein at 0, 10, 20, 30, 60, 90 and 120 minutes following glucose administration, and blood glucose levels were measured using a Glucometer Elite blood glucose meter (Bayer, Toronto, ON). For plasma insulin determinations, a blood sample (100 μ l) was removed from the tail vein during the 10-20 minute time period following glucose administration. Blood samples were immediately mixed with 10 U/ml heparin and plasma was separated by centrifugation at 4 °C and stored at -80 °C until assayed. Plasma was assayed for insulin using a mouse insulin ELISA kit (Linco Research, St. Charles, MO). For analysis of the acute effects of vildagliptin on glucagon levels, mice were fasted overnight, then treated either with water or 0.9 mg/ml vildagliptin in the water to a dose of 5 mg/kg mouse by oral gavage. After 20 min, mice were challenged with oral glucose (1.5 mg/g mouse) and 15 min later mice were euthanized and blood was collected by cardiac bleed in 10% TED (5,000 KIU/ml Trasylol, 1.2 mg/ml EDTA, and 0.1 nM Diprotin A). Plasma glucagon was measured using a Mouse Endocrine LINCOplex kit (LINCO Research, St. Charles, MO) following the manufacturer's protocol. Hemoglobin A1c (HbA1c) was measured using a DCA 2000+ Analyzer (Bayer, Toronto, ON). Levels of plasma cholesterol and triglycerides were measured using colorimetric assays (L-type TG kit and total Cholesterol kit - Wako chemicals (Richmond, VA)).

Analysis of β -cell area and β -cell proliferation. After 8 weeks of vildagliptin treatment, mice were injected i.p. with 100 mg/kg of 5-bromo-2'-deoxyuridine (BrdU; Sigma-Aldrich, St. Louis, MO) 16 h before being sacrificed. The pancreas was dissected from surrounding tissue, fixed overnight in 5% glacial acetic acid/25% formaldehyde (vol/vol), and embedded in paraffin. Histological sections were immunostained for insulin using rabbit anti-insulin (1:30 dilution; Dako Diagnostics, Mississauga, Ontario, Canada) as primary antibody and biotinylated goat anti-rabbit (1:200 dilution; Vector Labs, Burlington, Ontario, Canada) as secondary

antibody. The sections were then incubated with HRP-conjugated Ultra Streptavidin (ID Labs Inc., London, Ontario, Canada) for 30 minutes and colour was developed with freshly prepared 3,3'-diaminobenzidine tetrahydrochloride (DAB; Dako Diagnostics) solution. For assessment of β -cell replication, pancreatic sections were double-stained for insulin (as described above) and for BrdU using mouse anti-BrdU (1:1000 dilution; Caltag Laboratories, Burlingame, California) as primary antibody. Following the incubation with the primary antibody, sections were exposed to biotinylated horse anti-mouse IgG (1:200 dilution; Vector Labs, Burlington, ON) and subsequently stained with HRP-conjugated Ultra-Streptavidin (ID Labs Inc., London, ON) and colour was developed with freshly made 3,3-diaminobenzidine solution (NiDAB; Vector Labs Inc., Burlington, ON) solution. The sections were examined using a Leica microscope (Leica Microsystems, Wetzlar, Germany) equipped with a video camera and connected to a computer with imaging software (Qwin; Leica Microsystems, Richmond Hill, ON). β -cell area (area represented by insulin-immunopositive cells) was quantified using multiple histological sections from each pancreas and was expressed as a percentage of total pancreatic area as previously described (20-22).

Insulin Tolerance Tests. WT and DIRKO mice were fasted for five hours and given 1.7 U/kg insulin (Humulin R, 100U/ml; Lilly, Toronto, ON, Canada) by intraperitoneal injection. Blood glucose levels were monitored at regular intervals for 4h following insulin administration.

Pancreatic Insulin Content

Pancreas (15-20 mg) was minced and homogenized at 4 C in 5 ml pre-chilled acid-alcohol mix (800 ml reagent alcohol + 179 ml deionized water + 21 ml 12 N sulfuric acid). The homogenate was divided in two aliquots (500 μ l each) for assessment of insulin content and total protein. For analysis of insulin content, the pancreatic homogenate was centrifuged and insulin levels were measured in the clarified supernatant using an insulin RIA kit (LINCO Research, St. Charles, MO). For determination of total protein, the pancreatic homogenate was

dried, resuspended in 200 μ l of NaOH 1N and incubated at 55C. A Bradford assay was performed using 5 μ l of protein extract. Pancreatic insulin content was normalized to total protein content in each sample.

Assessment of Food Intake. Mice were fasted overnight (16-18 h), weighed and then placed into individual cages containing pre-weighed rodent chow, with free access to water. Food was reweighed at 2, 4, 8 and 24h and food intake was expressed as grams of food ingested/gram body weight

Indirect Calorimetry. Mice were placed into individual metabolic chambers with free access to food and water. Oxygen consumption was determined by indirect calorimetry using an Oxymax System (Columbus Instruments, Columbus, OH). VO_2 was measured at 15-minute intervals for a total of 21 hours and was normalized to body weight.

RNA preparation and Quantitative Real-Time

RT-PCR. Total RNA was extracted from the pancreas, intestine and liver using Trizol (Sigma-Aldrich, St. Louis, MO) and first-strand cDNA was synthesized from total RNA using the Superscript II synthesis system (Invitrogen, Carlsbad, CA) and random hexamers. Real-Time quantitative PCR analysis was performed using TaqMan® Gene Expression Assays and TaqMan® Universal PCR Master Mix (Applied Biosystems, Foster City, CA) using the ABI Prism 7900 Sequence Detection System according to the protocols provided by the manufacturer (Applied Biosystems, Melbourne, Australia). The relative mRNA transcript levels were calculated according to the $2^{-\Delta CT}$ method (23), ΔCT being the difference in cycle threshold values between the target mRNA and the 18S internal control.

Assessment of plasma DPP4 activity

Mice were fasted overnight and re-fed for 45 min prior to euthanization. Plasma was collected from the heart in 10 U/ml of heparin. 40 μ l of plasma was incubated at 37 C in the presence of Gly-Pro p-Nitroanilide (substrate) and the rate of its conversion into p-Nitroaniline by DPP4 enzymatic action was monitored at 0, 15, 30, 50 and 60 min. Color development was measured at 405 nm wavelength. A standard curve was

obtained with known concentrations of p-Nitroaniline. Concentration of p-Nitroaniline produced by DPP4 activity action on the substrate was calculated from standard curve. The kinetics of the enzymatic reaction are directly proportional to the slope of the curve calculated by linear regression. DPP4 activity is expressed as μM units of activity per minute of incubation with the substrate.

Isolation of mouse primary hepatocytes. Mice were anaesthetized using isoflurane and their abdominal cavity exposed. The superior vena cava was clamped, the portal vein transected, and the inferior vena cava perfused with 50 ml of filter-sterilized liver perfusion media pH 7.4 (Invitrogen-Gibco, Burlington, ON), immediately followed by 25 ml of liver digest media pH 7.4 (Invitrogen-Gibco, Burlington, ON). Both the perfusion and the digest media were maintained at 37°C and bubbled with oxygen. The liver was removed and hepatocytes were harvested in ice-cold hepatocyte wash media (Invitrogen-Gibco, Burlington, ON), sedimented by centrifugation at 50 x g for 5 min at 4°C, and then washed with hepatocyte wash media. Viable hepatocytes were obtained by Percoll density gradient centrifugation and resuspended in 10 ml of attachment media [Williams E media supplemented with 2mM glutMAX, 5% fetal bovine serum, 100U/ml penicillin, 100 $\mu\text{g}/\text{ml}$ streptomycin, (all from Invitrogen-Gibco, Burlington, ON), and 350 nM insulin]. Hepatocytes were seeded into 6-well plates and allowed to attach for 2 to 4 hours prior to lipid synthesis and secretion studies, or were grown overnight prior to cAMP production studies.

cAMP production in mouse primary hepatocytes. Mouse primary hepatocytes were maintained in Williams E medium supplemented with 0.1% fat-free bovine serum albumin. All peptides were dissolved in PBS and cells were treated with peptides in Williams E medium containing 100 μM IBMX. Cells were incubated with 1 μM exendin (9-39) or medium alone for 20 min at 37°C, followed by an additional 3h incubation in the presence of 100 nM of exendin-4, GLP-1, or glucagon. Cells incubated with 100 μM of Forskolin were used as a positive control.

All reactions were carried out in triplicate and terminated by the addition of ice-cold absolute ethanol. Cell extracts and media were collected and stored at -80°C until assayed. cAMP concentration was measured in desiccated aliquots of ethanol extracts using a cAMP radioimmunoassay (RIA) kit (Biomedical Technologies, Stoughton, MA).

Lipid synthesis and secretion in mouse primary hepatocytes. Mouse primary hepatocytes were seeded at a density of one million cells/well into 6-well plates and labeled with [H^3] acetate (Perkin Elmer, Waltham, MA; for fatty acid and cholesterol synthesis and secretion) and [H^3] oleate (Perkin Elmer, Waltham, MA; for cholesterol ester and triglyceride synthesis and secretion) in Williams E medium supplemented with 5% fetal bovine serum for 16 h in the presence of PBS or 20 nM of exendin-4 dissolved in PBS. Media was collected and the cells washed with PBS. Lipids were extracted twice from media and cells using hexane:isopropanol 3:2 (v/v). The organic solvent was evaporated under vacuum, lipids were resuspended in ice-cold hexane and resolved by thin layer chromatography (TLC). Areas of the TLC plate corresponding to lipid standards for cholesterol, fatty acids, triglycerides, and cholesterol esters were cut out and mixed overnight with scintillation cocktail. The radioactivity in each sample was measured by scintillation counting. Following lipid extraction, cells were lysed in 50 mM NaOH and protein content was determined using the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA). All reactions were carried out in quadruplicate.

Statistical Analysis. All results are expressed as mean \pm SE. Statistical significance was assessed by ANOVA and, where appropriate, a Student's t-test using GraphPad Prism 3 (GraphPad Software, San Diego, CA). A *P* value of <0.05 was considered to be statistically significant.

Results

To ascertain whether continuous administration of vildagliptin (supplied at 1 $\mu\text{mol}/\text{ml}$ in the drinking water) was associated with suppression of plasma DPP4 activity, we measured DPP-4 activity after 8 weeks of vildagliptin

administration. Plasma DPP4 activity was significantly reduced in WT mice treated with vildagliptin (Figure 1, $p < 0.001$). Furthermore, baseline plasma DPP4 activity was even lower in DIRKO mice relative to wildtype mice and even more markedly suppressed in DIRKO mice treated with vildagliptin (Figure 1). These findings illustrate that continuous administration of vildagliptin suppresses plasma DPP4 activity in both WT and DIRKO mice.

Vildagliptin treatment for 7 weeks significantly reduced glycemic excursion after oral glucose loading in WT mice, in association with an increase in plasma levels of insulin (Figure 2A-C). In contrast, vildagliptin had no effect on glycemic excursion or levels of plasma insulin in DIRKO mice (Figure 2A-C). Although plasma glucagon levels were not significantly different following chronic vildagliptin therapy in WT or DIRKO mice (Figure 2D), acute administration of vildagliptin was associated with marked suppression of plasma glucagon in WT but not DIRKO mice (data not shown).

To determine whether the improvement in glucose tolerance observed in WT mice following vildagliptin therapy was due in part to incretin-mediated changes in body weight and/or insulin sensitivity, we assessed energy expenditure, food intake, body weight, and the glycemic response to insulin administration in WT and DIRKO mice. Although body weight gain was significantly greater in high fat-fed WT vs. DIRKO mice as described (21), vildagliptin treatment had no effect on body weight, food intake, or energy expenditure in WT or DIRKO mice (Supplementary Figure 1A-D [available at <http://diabetes.diabetesjournals.org>]). Moreover, fat mass and lean body mass were comparable in WT vs DIRKO mice at the start of the study and we did not detect changes in these parameters after vildagliptin treatment of WT or DIRKO mice (Supplementary Figure 1G,H). Although DIRKO mice were more sensitive to exogenous insulin administration as previously described (21), vildagliptin had no effect on the rate of reduction or recovery of plasma glucose observed following insulin administration in WT or DIRKO mice (Supplementary Figure 2).

As exogenous administration of GLP-1 or GIP has been associated with expansion of islet mass via enhancement of β -cell proliferation and survival (24), we examined islet histology in WT and DIRKO mice. No differences in β -cell area or β -cell replication were observed in WT or DIRKO mice following vildagliptin administration (Figure 3A-D), although vildagliptin-treated WT mice exhibited a modest but non-significant increase in β -cell area after 8 weeks of therapy (Figure 3A). Furthermore, no differences in β -cell replication were observed in WT or DIRKO mice following vildagliptin administration (Figure 3A-D) and vildagliptin had no significant effect on levels of pancreatic insulin content (Figure 3E) or HbA1c (Figure 3F). We next analyzed the expression of a panel of genes known to be important for the function of differentiated islet cells, some of which have been shown to be induced following administration of GLP-1R agonists (1). Vildagliptin treatment had no significant effect on levels of mRNA transcripts for insulin, glucagon, amylin, glucokinase, cyclic AMP response element binding protein (CREB), or pancreatic and duodenal homeobox-1, in WT or DIRKO mice (Figure 4).

Vildagliptin administration for 4 weeks improved plasma lipid profiles in subjects with type 2 diabetes (25). Accordingly we assessed plasma lipids in WT and DIRKO mice. Vildagliptin therapy was associated with a significant reduction in levels of plasma cholesterol in WT mice (Figure 5A). In contrast, although levels of plasma cholesterol and triglycerides were lower in DIRKO vs. WT mice, no changes in plasma lipids were observed following vildagliptin treatment in DIRKO mice (Figure 5A, B).

To determine whether the reduction in plasma lipids observed in vildagliptin-treated WT mice was associated with changes in the expression of hepatic genes encoding enzymes important for lipid biosynthesis or oxidation, we compared the levels of specific mRNA transcripts in liver from vildagliptin- or vehicle-treated WT and DIRKO mice (Table 1 and Fig 5 C, D). Several distinct gene expression profiles were observed in liver

RNA samples from WT and DIRKO mice. A significant reduction in levels of hepatic mRNA transcripts for phosphomevalonate kinase (MVK), Diphosphomevalonate decarboxylase (MVD), farnesyl diphosphate transferase 1 (Fdft1), acyl-coA dehydrogenase (ACADM), and long chain acyl Coa synthetase (Acs11) was observed following vildagliptin treatment of WT mice (Figure 5C,D). In contrast to the lack of effect of vildagliptin on glucose tolerance or plasma lipids in DIRKO mice, vildagliptin therapy was associated with reduction in levels of Fdft1, Acetyl-Coenzyme A Acyltransferase (Acaa1) and carnitine palmitoyltransferase 1 (CPT1) mRNA transcripts in DIRKO mice (Figure 5D). A third grouping of mRNA transcripts encoding for enzymes involved in the lipid biosynthesis or oxidation pathways represented genes whose expression patterns were not changed by Vildagliptin treatment in either WT or DIRKO mice, including squalene epoxidase, acyl-coenzyme A Carboxylase beta, Stearoyl CoA desaturase 1 (SCD1), Fatty acid desaturase 1 and 2 (Fads1 and Fads2), and Carnitine acetyltransferase (Crat) (Table 1 and Supplementary Figure 3).

As human studies have demonstrated that vildagliptin administration to subjects with type 2 diabetes was associated with reduction in plasma levels of intestinal-derived triglyceride rich lipoproteins (25), we examined whether vildagliptin treatment of WT or DIRKO mice was associated with changes in the expression of genes encoding key enzymes involved in intestinal lipid transport and/or biosynthesis. Vildagliptin had no effect on levels of intestinal mRNA transcripts for microsomal triglyceride transfer protein (MTTP), Fatty acid transport protein 1 (FATP1), apolipoprotein B mRNA editing enzyme (ApoBec)-1, or lipoprotein lipase (Lpl) (Figure 5E).

We hypothesized that vildagliptin, by enhancing levels of bioactive GLP-1, might directly modulate hepatic lipid synthesis or secretion. As GLP-1 and exendin-4 were reported to regulate the expression of genes encoding enzymes involved in lipid synthesis and oxidation in rat hepatocytes through a GLP-1 receptor-dependent pathway (26), we assessed

whether the GLP-1R agonist exendin-4 was capable of directly regulating lipid synthesis or secretion in WT murine hepatocytes *in vitro*. In contrast to data obtained with rat hepatocytes, exendin-4 had no effect on cholesterol, cholesterol ester, free fatty acid, or triglyceride synthesis or secretion in murine hepatocytes (Figure 6). Furthermore, we did not detect GLP-1R mRNA transcripts by PCR analysis of RNA isolated from cultured murine hepatocytes (data not shown) and we were unable to detect any stimulation of cyclic AMP formation following incubation of murine hepatocytes with GLP-1 or exendin-4. In contrast, both glucagon and forskolin significantly increased levels of hepatocyte cyclic AMP in the same experiments (Supplementary Figure 4).

As therapy with DPP4 inhibitors such as vildagliptin and sitagliptin has been associated with increased plasma levels of GLP-1 and GIP in both the fasting and postprandial states (27; 28), we assessed whether vildagliptin modulates incretin biosynthesis by examining the levels of mRNA transcripts for GIP and proglucagon in the duodenum and ileum of WT mice. No changes in the relative levels of proglucagon, GIP or DPP4 mRNA transcripts were detected in the small bowel of mice treated with vildagliptin for 8 weeks relative to vehicle-treated control mice, indicating that chronic DPP4 inhibition is not associated with induction of incretin gene expression (Supplementary Figure 5).

Discussion

DPP4 is a ubiquitously expressed protease that exists as both a membrane anchored protein and a soluble form widely distributed in the circulation. Both molecular species of DPP4 retain their catalytic activity, and are capable of cleaving a broad spectrum of peptides with an alanine or proline at position two (29). The best characterized DPP4 substrates with glucoregulatory activity are the incretin peptides GIP and GLP-1. Circulating levels of intact GLP-1 and GIP are dependent on the presence of DPP4 activity, as DPP4^{-/-} mice exhibit increased circulating levels of intact incretin peptides (11) and therapy with DPP4 inhibitors is associated with increased levels of bioactive GIP and GLP-

1 . These findings, taken together with the demonstration that the acute glucose-lowering actions of DPP4 inhibitors are abrogated in DIRKO mice (20), strongly implicate an important role for GIP and GLP-1 as key transducers of the anti-diabetic actions of DPP4 inhibitors.

Nevertheless, the observation that multiple additional DPP4 substrates regulate food intake and β -cell function, including enterostatin, PACAP, GRP, PYY and oxyntomodulin, raises the possibility that DPP4 inhibition may lower blood glucose and/or produce other biological actions via modulation of peptide activity beyond GLP-1 and GIP (15; 29). Furthermore, although DPP4 inhibitors fail to lower blood glucose in acute short term studies in normoglycemic DIRKO mice (20), it remains possible that chronic therapy with DPP4 inhibitors in high fat-fed DIRKO mice may recruit additional substrates that contribute to the reduction in glycemia observed following prolonged DPP4 inhibition *in vivo*. Our data demonstrating complete absence of glucose regulation in high fat fed DIRKO mice following chronic continuous vildagliptin administration suggests that the GIP and GLP-1 receptors represent the predominant molecular targets for glucoregulation following sustained DPP4 inhibition *in vivo*. Continuous vildagliptin administration was not associated with reduction of blood glucose, inhibition of plasma glucagon, or stimulation of insulin secretion in DIRKO mice.

An important limitation of the current studies is the degree of glucose intolerance achieved following chronic high fat feeding in our experiments. Although plasma glucose levels ranged from 8-10 in the fasting state and rose to ~ 20 mM after glucose challenge, it remains possible that conditions employing more severe hyperglycemia and more potent or prolonged DPP4 inhibition may reveal activities of additional DPP4 substrates beyond GLP-1 and GIP that might contribute to glucose reduction following chronic DPP4 inhibition.

In this regard, it is perhaps surprising that DPP4 inhibition was not associated with induction of incretin-responsive genes in the

pancreas (such as *pdx-1*, insulin, or glucokinase), and we did not detect significant stimulation of β -cell proliferation or expansion of β -cell mass following vildagliptin therapy in our experiments. One simple explanation may be that the degree of DPP4 inhibition achieved in WT mice in our experiments may not be sufficient to achieve required levels of plasma incretins necessary for optimal effects on β -cell mass. Other studies have shown that DPP4 inhibition was associated with normalization but not expansion of β -cell mass in high fat fed mice treated with des-fluoro-sitagliptin after streptozotocin administration (30). Similarly, chronic vildagliptin treatment of mice with β -cell expression of human islet amyloid polypeptide improved islet topography but did not result in significant expansion of β -cell mass (31). Hence, these studies imply that pharmacological levels of GLP-1 or GLP-1R agonists, not achieved with DPP4 inhibition, may be required for optimal expansion of β -cell mass in preclinical experiments.

Consistent with findings that vildagliptin lowers plasma cholesterol and triglycerides in subjects with type 2 diabetes (25), vildagliptin decreased levels of plasma cholesterol and triglycerides in wildtype mice. These findings were associated with significant changes in levels of hepatic enzymes important for cholesterol biosynthesis and/or lipid oxidation in both WT and DIRKO mice. Nevertheless, we did not observe any direct effect of GLP-1 on cholesterol or triglyceride synthesis or secretion in isolated murine hepatocytes. Hence, the reduction of plasma cholesterol observed following chronic DPP4 inhibition may be related in part to as yet unexplained effects of GLP-1 on intestinal lipid synthesis or secretion as postulated in human studies (25) or to indirect actions reflecting improved plasma glucose in vildagliptin-treated mice.

In contrast to the lack of vildagliptin-induced changes in parameters regulating glucose homeostasis in DIRKO mice, vildagliptin therapy selectively reduced the hepatic expression of *Fdft1*, *Acaa1*, and *Cpt1* in DIRKO mice. These data illustrate that the mechanisms underlying the reduction in levels of cholesterol

and triglycerides observed in conjunction with DPP4 inhibitor therapy (25) are likely complex, reflecting both the gluoregulatory actions of GIP and GLP-1, and additional, as yet unidentified DPP4-sensitive substrates. Although DPP4 is known to be expressed in hepatocytes, there is currently no data linking changes in liver DPP4 activity to enzymatic regulation of lipid synthesis and secretion. An important caveat of our studies is that we examined the effects of only a single DPP-4 inhibitor, vildagliptin, and hence we cannot be certain that some of the findings we observed were not specific to vildagliptin alone. Taken together, these data demonstrate that the GIP and GLP-1 receptors

are essential for many but not all of the changes in metabolic parameters observed following chronic inhibition of DPP4. Our data suggest that additional studies characterizing the importance of DPP4 in the control of hepatic lipid synthesis and oxidation appear warranted.

Acknowledgements

These studies were supported in part by grants from Novartis Pharmaceuticals Inc, the Canadian Diabetes Association and the Juvenile Diabetes Research Foundation. GF is supported by a Canada Graduate Studentship Award from the CIHR. DJD is supported by a Canada Research Chair in Regulatory Peptides.

References

1. Drucker DJ: The biology of incretin hormones. *Cell Metab* 3:153-165, 2006
2. Todd JF, Wilding JP, Edwards CM, Ghatgei MA, Bloom SR: Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus. *Eur J Clin Invest* 27:533-536, 1997
3. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. *Lancet* 359:824-830, 2002
4. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ: Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH₂-terminus in type II diabetic patients and in healthy subjects. *Diabetes* 44:1126-1131, 1995
5. Ruiz-Grande C, Pintado J, Alarcon C, Castilla C, Valverde I, Lopez-Novoa JM: Renal catabolism of human glucagon-like peptides 1 and 2. *Can J Physiol Pharmacol* 68:1568-1573, 1990
6. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP: Isolation and characterization of exendin 4, an exendin 3 analogue from *Heloderma suspectum* venom. *J Biol Chem* 267:7402-7405, 1992
7. Drucker DJ, Nauck MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. *Lancet* 368:1696-1705, 2006
8. Mentlein R, Gallwitz B, Schmidt WE: Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. *Eur J Biochem* 214:829-835, 1993
9. Kieffer TJ, McIntosh CH, Pederson RA: Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. *Endocrinology* 136:3585-3596, 1995
10. Hansen L, Deacon CF, Orskov C, Holst JJ: Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. *Endocrinology* 140:5356-5363, 1999
11. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U, Watanabe T, Drucker DJ, Wagtman N: Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. *Proc Natl Acad Sci U S A* 97:6874-6879, 2000
12. Conarello SL, Li Z, Ronan J, Roy RS, Zhu L, Jiang G, Liu F, Woods J, Zychband E, Moller DE, Thornberry NA, Zhang BB: Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. *Proc Natl Acad Sci U S A* 100:6825-6830, 2003
13. Ahren B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, Sandqvist M, Bavenholm P, Efendic S, Eriksson JW, Dickinson S, Holmes D: Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. *Diabetes Care* 25:869-875, 2002
14. Ahren B: Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. *Diabetes Care* 30:1344-1350, 2007
15. Drucker DJ: Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. *Diabetes Care* 30:1335-1343, 2007
16. Ahren B, Hughes TE: Inhibition of DPP-4 Augments Insulin Secretion in Response to Exogenously Administered GLP-1, GIP, PACAP and GRP in Mice. *Endocrinology* 4:2055-2059, 2005
17. Zhu L, Tamvakopoulos C, Xie D, Dragovic J, Shen X, Fenyk-Melody JE, Schmidt K, Bagchi A, Griffin PR, Thornberry NA, Sinha Roy R: The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38). *J Biol Chem* 278:22418-22423, 2003
18. Jarrousse C, Bataille D, Jeanrenaud B: A pure enteroglucagon, oxyntomodulin (glucagon 37), stimulates insulin release in perfused rat pancreas. *Endocrinology* 115:102-105, 1984

19. Ahren B: What mediates the benefits associated with dipeptidyl peptidase-IV inhibition? *Diabetologia* 48:605-607, 2005
20. Hansotia T, Baggio LL, Delmeire D, Hinke SA, Yamada Y, Tsukiyama K, Seino Y, Holst JJ, Schuit F, Drucker DJ: Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. *Diabetes* 53:1326-1335, 2004
21. Hansotia T, Maida A, Flock G, Yamada Y, Tsukiyama K, Seino Y, Drucker DJ: Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. *J Clin Invest* 117:143-152, 2007
22. Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jette L, Benquet C, Drucker DJ: Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. *Diabetes* 52:751-759, 2003
23. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 25:402-408, 2001
24. Drucker DJ: Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. *Mol Endocrinol* 17:161-171, 2003
25. Matikainen N, Manttari S, Schweizer A, Ulvestad A, Mills D, Dunning BE, Foley JE, Taskinen MR: Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. *Diabetologia* 49:2049-2057, 2006
26. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA: Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. *Hepatology* 43:173-181, 2006
27. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE: Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed {beta}-Cell Function in Patients with Type 2 Diabetes. *J Clin Endocrinol Metab* 90:4888-4994, 2005
28. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA: Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes. *J Clin Endocrinol Metab*, 2006
29. Mentlein R: Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides. *Regul Pept* 85:9-24, 1999
30. Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, Feng Y, Zhu L, Li C, Howard AD, Moller DE, Thornberry NA, Zhang BB: Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic {beta}-Cell Mass and Function in a Rodent Model of Type 2 Diabetes. *Diabetes* 55:1695-1704, 2006
31. Ahren B, Winzell MS, Wierup N, Sundler F, Burkey B, Hughes TE: DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide. *Regul Pept*, 2007

Table 1 Vildagliptin-regulated hepatic gene expression

Gene	WT	DIRKO
Mvk	+	-
Acadm	+	-
Acs11	+	-
Mvd	+	-
Fdft1	+	+
Cpt1	-	+
Acaa1	-	+
Crat	-	-
Acads	-	-
Hadha	-	-
Apo-4	-	-
Apo-C	-	-
Apo-m	-	-
Lipg	-	-
Acab	-	-
Fads1	-	-
Fads 2	-	-
Scd1	-	-

Lss	-	-
Dhcr7	-	-
Sqle	-	-

Table 1 Legend + = significant effect of vildagliptin in levels of mRNA transcripts; - denotes lack of effect of vildagliptin. WT = wild type mice, DIRKO = dual incretin receptor knockout mice.

Abbreviation of mRNA transcripts as per gene nomenclature for murine genes.

Figure Legends

Figure 1

Vildagliptin reduces DPP4 activity in C57BL/6 WT and DIRKO mice after 8 weeks of therapy. Plasma samples were collected at the end of the 8 week experiment in 10 U/ml heparin (n = 9 mice per group). DPP4 activity was measured by a colorimetric assay using Gly-Pro p-Nitroanilide as substrate. Color development due to the conversion of the substrate into p-Nitroaniline by DPP4 enzymatic action was measured at times 0, 15, 30, 45, 60 minutes (405 nm wavelength). *** = P < 0.001

Figure 2

Vildagliptin significantly reduces glycemic excursion and increases levels of glucose-stimulated plasma insulin following an oral glucose tolerance test (OGTT) in C57BL/6 WT mice but not in DIRKO mice. (A) OGTT in WT and DIRKO mice, following treatment with vehicle or vildagliptin (n = 8-9 per group). (B) Area Under the Curve (AUC) for total glycemic excursion during the OGTT, * = p < 0.05. (C, D) Plasma Insulin (C) and Plasma Glucagon (D) levels at the 10–20 minute time point following glucose administration. * = P < 0.05

Figure 3

Vildagliptin therapy has no effect on β -cell area in C57BL/6 WT or in DIRKO mice after 8 weeks of treatment. (A, B) Total β -cell area per total pancreatic area (n = 13- 14 mice per group). Histological sections from the pancreas were stained for insulin as described in methods and insulin- positive β -cell area was measured and normalized for total section area. (C, D) Number of BrdU+ β - cells per pancreatic area (n = 8-9 mice per group). Sections were stained for BrdU as described in methods and Insulin positive BrdU+ cells were counted and normalized for pancreatic area. (E,F) Levels of HbA1c (E), and pancreatic insulin content (F) were determined in WT and DIRKO mice as described in Methods.

Figure 4

Relative levels of pancreatic mRNA transcripts in vildagliptin-treated WT and DIRKO mice. Levels of pancreatic mRNA transcripts for glucagon, insulin, amylin, PDX-1, CREB and glucokinase were determined by Real Time PCR and normalized to levels of 18S ribosomal RNA.

Figure 5

Eight weeks of vildagliptin treatment reduces postprandial plasma levels of cholesterol in C57 BL/6 WT but not in DIRKO mice. (A, B) Mice were fasted over night and re-fed for 45 min before plasma was collected in 10 U/ml of heparin. Plasma concentrations of cholesterol and triglycerides were measured using Wako Cholesterol E and Wako L-Type TG-H kits respectively following manufacturer specifications. (C) Vildagliptin regulates the expression of genes involved in hepatic cholesterol biosynthesis, fatty acid synthesis and fatty acid beta oxidation. Relative levels of mRNA transcripts, as determined by Real Time PCR, are shown, normalized to levels of 18s mRNA transcripts analyzed in the same samples and experiments.

Figure 6

The GLP-1R agonist exendin-4 does not stimulate lipid synthesis or secretion in mouse primary hepatocytes. Lipid synthesis and secretion was measured in mouse primary hepatocytes following a 16 h treatment with either PBS or 40 nM exendin-4 (Ex-4). Lipid secretion was quantified using lipids extracted from the culture media, whereas lipid synthesis was quantified using the sum of lipids extracted from the culture media and cells. The data are means \pm SE of reactions carried out in quadruplicate.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6